NBRV News and Press, Nabriva Therapeutics plc From 05/05/22

Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M. For further details see: Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eastern Ti...

Ireland's Nabriva Therapeutics (NASDAQ:NBRV) said it extend its exclusive agreement with Merck (MRK) to promote and distribute the Kenilworth, N.J.-based company's antibacterial drug Sivextro in the U.S. till Dec. 31, 2026. Sivextro (tedizolid phosphate) is used to treat patients 12...

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agr...

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will repo...

DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patien...

Investment analysts at Northland Securities have lowered their price target on commercial-stage biopharmaceutical company Nabriva Therapeutics (NBRV -9.1%). In a research note published today, the brokerage slashed NBRV's PT from $4.00 to $2.00, while keeping an "Outperform" rating on the sto...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2021 Q4 earnings call. For further details see: Nabriva Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation

Nabriva Therapeutics plc (NBRV) Q4 2021 Results Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Steve Gelone - President and Chief Operating Officer Conference Call Participants Carl Byrnes -...

The commercial-stage pharma company, Nabriva Therapeutics (NASDAQ:NBRV) is trading ~9% lower in the post-market Tuesday after announcing its 4Q 2021 results, which indicated a slowdown in its growth momentum. Revenue for the quarter more than tripled to $9.3M, backed by $8.4M in net...